191 related articles for article (PubMed ID: 38811702)
1. How antibody-drug conjugates aim to take down cancer.
Plackett B
Nature; 2024 May; 629(8014):S2-S3. PubMed ID: 38811702
[No Abstract] [Full Text] [Related]
2. Antibody Drug Conjugates for Cancer Therapy.
Polakis P
Pharmacol Rev; 2016 Jan; 68(1):3-19. PubMed ID: 26589413
[TBL] [Abstract][Full Text] [Related]
3. Weaponized antibodies use new tricks to fight cancer.
Ledford H
Nature; 2016 Nov; 540(7631):19-20. PubMed ID: 27905466
[No Abstract] [Full Text] [Related]
4. Antibody-Drug Conjugates.
Peng L; Chen X
Bioconjug Chem; 2015 Nov; 26(11):2169. PubMed ID: 26577284
[No Abstract] [Full Text] [Related]
5. Safety and Tolerability of Antibody-Drug Conjugates in Cancer.
Wolska-Washer A; Robak T
Drug Saf; 2019 Feb; 42(2):295-314. PubMed ID: 30649747
[TBL] [Abstract][Full Text] [Related]
6. Picking the optimal target for antibody-drug conjugates.
Mathur R; Weiner GJ
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714470
[TBL] [Abstract][Full Text] [Related]
7. Naptumomab estafenatox: a new immunoconjugate.
Robinson MK; Alpaugh RK; Borghaei H
Expert Opin Biol Ther; 2010 Feb; 10(2):273-9. PubMed ID: 20053143
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer.
Drachman JG; Senter PD
Hematology Am Soc Hematol Educ Program; 2013; 2013():306-10. PubMed ID: 24319196
[TBL] [Abstract][Full Text] [Related]
9. Antibody drug conjugates: lessons from 20 years of clinical experience.
Tolcher AW
Ann Oncol; 2016 Dec; 27(12):2168-2172. PubMed ID: 27733376
[TBL] [Abstract][Full Text] [Related]
10. Noninternalizing targeted cytotoxics for cancer therapy.
Casi G; Neri D
Mol Pharm; 2015 Jun; 12(6):1880-4. PubMed ID: 25738312
[TBL] [Abstract][Full Text] [Related]
11. Linked-in: design and efficacy of antibody drug conjugates in oncology.
Feld J; Barta SK; Schinke C; Braunschweig I; Zhou Y; Verma AK
Oncotarget; 2013 Mar; 4(3):397-412. PubMed ID: 23651630
[TBL] [Abstract][Full Text] [Related]
12. Antibody drug conjugates.
Teicher BA
Curr Opin Oncol; 2014 Sep; 26(5):476-83. PubMed ID: 25024051
[TBL] [Abstract][Full Text] [Related]
13. Antibody-Drug Conjugates-A Tutorial Review.
Baah S; Laws M; Rahman KM
Molecules; 2021 May; 26(10):. PubMed ID: 34063364
[TBL] [Abstract][Full Text] [Related]
14. What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?
Esteva FJ; Miller KD; Teicher BA
Am Soc Clin Oncol Educ Book; 2015; ():e117-25. PubMed ID: 25993162
[TBL] [Abstract][Full Text] [Related]
15. Novel linkers and connections for antibody-drug conjugates to treat cancer and infectious disease.
Pillow TH
Pharm Pat Anal; 2017 Jan; 6(1):25-33. PubMed ID: 28155578
[TBL] [Abstract][Full Text] [Related]
16. Antibody-drug conjugates: What drives their progress?
Pander G; Uhl P; Kühl N; Haberkorn U; Anderl J; Mier W
Drug Discov Today; 2022 Oct; 27(10):103311. PubMed ID: 35787480
[TBL] [Abstract][Full Text] [Related]
17. Unveiling the Untapped Potential of Antibody Drug Conjugates in Precision Oncology.
Trapani D; Katrini J; Curigliano G
JAMA Oncol; 2024 May; 10(5):563-564. PubMed ID: 38483383
[TBL] [Abstract][Full Text] [Related]
18. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
[TBL] [Abstract][Full Text] [Related]
19. Challenges in the development and manufacturing of antibody-drug conjugates.
Ducry L
Methods Mol Biol; 2012; 899():489-97. PubMed ID: 22735971
[TBL] [Abstract][Full Text] [Related]
20. Antibody drug conjugates.
Bakhtiar R
Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
